Tags

Type your tag names separated by a space and hit enter

Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation.
J Affect Disord 2008; 111(2-3):351-9JA

Abstract

BACKGROUND

Effect of fish oil supplementation in parkinsonian patients with depression measured by Montgomery-Asberg Rating Scale (MADRS), the Clinical Global Impressions Scale (CGI) and Beck Depression Inventory (BECK).

METHOD

Double-blind, placebo-controlled study analyzed depression in 31 patients with Parkinson's Disease and Major Depression (DSM-IV). The patients were double-blind separated in 2 groups that received fish oil (containing omega-3 fatty acids) or mineral oil capsules for 3 months; each group was separated in 2 new groups: one taking antidepressant medication and another one not taking it.

RESULTS

29 patients completed the 12-week trial, 58% were female and the mean age was 64.4 years old. Patients supplemented with fish oil showed a significant decrease in MADRS and CGI-Depression scores, and there was no difference among groups in BDI. 14 patients (42%) met criteria for > or = 50% reduction in MADRS score, 7 patients (22%) met criteria for remission (final MADRS total score < or = 12), and 2 patients (6%) discontinued supplementation of fish oil. HPLC analysis of fatty-acid profile showed increase of omega-3 fatty acid in the erythrocyte membrane of patients taking fish oil.

CONCLUSION

These results reveal that PD patients taking fish oil, with or without antidepressants, presented improvement in depressive symptoms and indicate that the intake of omega-3 can be used with an antidepressant effect or as adjuvant therapy with some other medication. This is a first pilot study with parkinsonian patients and omega-3 supplementation and requires replication in a larger sample.

Authors+Show Affiliations

Laboratório de Neurofisiologia, Departamento de Fisiologia, Universidade Federal do Paraná, C.P. 19.031, 81.531-990 Curitiba, PR, Brazil.No affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info availableNo affiliation info available

Pub Type(s)

Comparative Study
Journal Article
Randomized Controlled Trial

Language

eng

PubMed ID

18485485

Citation

da Silva, Ticyana Moralez, et al. "Depression in Parkinson's Disease: a Double-blind, Randomized, Placebo-controlled Pilot Study of Omega-3 Fatty-acid Supplementation." Journal of Affective Disorders, vol. 111, no. 2-3, 2008, pp. 351-9.
da Silva TM, Munhoz RP, Alvarez C, et al. Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. J Affect Disord. 2008;111(2-3):351-9.
da Silva, T. M., Munhoz, R. P., Alvarez, C., Naliwaiko, K., Kiss, A., Andreatini, R., & Ferraz, A. C. (2008). Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. Journal of Affective Disorders, 111(2-3), pp. 351-9. doi:10.1016/j.jad.2008.03.008.
da Silva TM, et al. Depression in Parkinson's Disease: a Double-blind, Randomized, Placebo-controlled Pilot Study of Omega-3 Fatty-acid Supplementation. J Affect Disord. 2008;111(2-3):351-9. PubMed PMID: 18485485.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Depression in Parkinson's disease: a double-blind, randomized, placebo-controlled pilot study of omega-3 fatty-acid supplementation. AU - da Silva,Ticyana Moralez, AU - Munhoz,Renato Puppi, AU - Alvarez,Cristiano, AU - Naliwaiko,Katya, AU - Kiss,Agata, AU - Andreatini,Roberto, AU - Ferraz,Anete Curte, Y1 - 2008/05/15/ PY - 2007/11/30/received PY - 2008/03/11/revised PY - 2008/03/12/accepted PY - 2008/5/20/pubmed PY - 2009/1/24/medline PY - 2008/5/20/entrez SP - 351 EP - 9 JF - Journal of affective disorders JO - J Affect Disord VL - 111 IS - 2-3 N2 - BACKGROUND: Effect of fish oil supplementation in parkinsonian patients with depression measured by Montgomery-Asberg Rating Scale (MADRS), the Clinical Global Impressions Scale (CGI) and Beck Depression Inventory (BECK). METHOD: Double-blind, placebo-controlled study analyzed depression in 31 patients with Parkinson's Disease and Major Depression (DSM-IV). The patients were double-blind separated in 2 groups that received fish oil (containing omega-3 fatty acids) or mineral oil capsules for 3 months; each group was separated in 2 new groups: one taking antidepressant medication and another one not taking it. RESULTS: 29 patients completed the 12-week trial, 58% were female and the mean age was 64.4 years old. Patients supplemented with fish oil showed a significant decrease in MADRS and CGI-Depression scores, and there was no difference among groups in BDI. 14 patients (42%) met criteria for > or = 50% reduction in MADRS score, 7 patients (22%) met criteria for remission (final MADRS total score < or = 12), and 2 patients (6%) discontinued supplementation of fish oil. HPLC analysis of fatty-acid profile showed increase of omega-3 fatty acid in the erythrocyte membrane of patients taking fish oil. CONCLUSION: These results reveal that PD patients taking fish oil, with or without antidepressants, presented improvement in depressive symptoms and indicate that the intake of omega-3 can be used with an antidepressant effect or as adjuvant therapy with some other medication. This is a first pilot study with parkinsonian patients and omega-3 supplementation and requires replication in a larger sample. SN - 0165-0327 UR - https://www.unboundmedicine.com/medline/citation/18485485/Depression_in_Parkinson's_disease:_a_double_blind_randomized_placebo_controlled_pilot_study_of_omega_3_fatty_acid_supplementation_ L2 - https://linkinghub.elsevier.com/retrieve/pii/S0165-0327(08)00128-6 DB - PRIME DP - Unbound Medicine ER -